Free Delivery Over $100
|
|
|||
|
||||
OverviewExamines the development and behavioral characteristics of HIV protease inhibitors from clinical and scientific perspectives. Discusses how protease inhibitors changed the FDA approval process. Highlights protease inhibitors as the cornerstone drugs of the first HAART regimens. Full Product DetailsAuthor: Richard C. Ogden (Senior Director of Scientific Development, Agouron Pharmaceuticals, San Diego, California, USA) , Charles Flexner (The John Hopkins University, Baltimore, Maryland, USA) , Richard C. Ogden , Charles W. FlexnerPublisher: Taylor & Francis Inc Imprint: Marcel Dekker Inc Volume: v. 25 Dimensions: Width: 21.60cm , Height: 2.10cm , Length: 27.90cm Weight: 0.590kg ISBN: 9780824704612ISBN 10: 0824704614 Pages: 328 Publication Date: 24 January 2001 Audience: College/higher education , Professional and scholarly , Undergraduate , Postgraduate, Research & Scholarly Format: Hardback Publisher's Status: Out of Stock Indefinitely Availability: Awaiting stock  Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
